Form 8-K

8-K — Guardant Health, Inc.

Accession: 0001576280-26-000036

Filed: 2026-07-30

Period: 2026-07-30

CIK: 0001576280

SIC: 8071 (SERVICES-MEDICAL LABORATORIES)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — gh-20260730.htm (Primary)

EX-99.1 (gh-06302026xexhibit991.htm)

GRAPHIC (image.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: gh-20260730.htm · Sequence: 1

gh-20260730

0001576280false00015762802026-07-302026-07-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): July 30, 2026

GUARDANT HEALTH, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-38683

45-4139254

(State or other jurisdiction

of incorporation or organization)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

3100 Hanover Street

Palo Alto, California 94304

(Address of principal executive offices) (Zip Code)

855-698-8887

(Registrant’s telephone number, include area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.00001 par value per share

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On July 30, 2026, Guardant Health, Inc. (the “Company”) issued a press release announcing financial results for the fiscal quarter ended June 30, 2026. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information furnished in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description

99.1

Press release of Guardant Health, Inc., dated July 30, 2026

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GUARDANT HEALTH, INC.

Date: July 30, 2026 By:

/s/ Michael Bell

Michael Bell

Chief Financial Officer

(Principal Accounting Officer and Principal Financial Officer)

EX-99.1

Filename: gh-06302026xexhibit991.htm · Sequence: 2

Document

Guardant Health Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

Second quarter 2026 revenue growth of 44% driven by strong performance in Oncology and Screening

Raises 2026 revenue guidance to $1.34 to $1.36 billion, representing growth of 36% to 38%

PALO ALTO, Calif. July 30, 2026 – Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended June 30, 2026.

Second Quarter 2026 Financial Highlights

For the three-month period ended June 30, 2026, as compared to the same period of 2025:

•Reported total revenue of $335.0 million, an increase of 44%, driven by:

◦Oncology revenue of $219.1 million, an increase of 38%, and approximately 104,000 oncology tests, an increase of 63%

◦Biopharma & Data revenue of $60.9 million, an increase of 9%

◦Screening revenue of $52.9 million, and approximately 66,000 Shield™ screening tests, compared to $14.8 million revenue and 16,000 tests in the prior year period

•Generated non-GAAP gross margin of 67%, compared to 66% for the second quarter of 2025

Recent Operating Highlights

•Received U.S. Food and Drug Administration (FDA) approval for Guardant360® Liquid CDx, the most advanced FDA-approved liquid biopsy panel

•Presented 38 abstracts at the 2026 American Society of Clinical Oncology Annual Meeting, highlighting the expanding clinical utility of Guardant’s portfolio

•Received FDA approval for Guardant360® CDx as a companion diagnostic for Boehringer Ingelheim’s HERNEXEOS for HER2 (ERBB2)-mutant advanced non-small cell lung cancer

•Achieved inclusion of Shield in the American Cancer Society’s updated colorectal cancer screening guidelines

•Obtained Shield coverage from UnitedHealth Group, the first major commercial insurer to provide coverage

•Received FDA approval for higher-throughput, lower-COGS Shield workflow

“Our second-quarter performance reflected broad-based momentum across the Guardant portfolio, with revenue increasing 44% year over year,” said Helmy Eltoukhy, co-founder and co-CEO. “Growth was fueled by strong oncology volume, with acceleration across every product. The landmark FDA approval of Guardant360 Liquid CDx further strengthens our portfolio and positions us to drive sustained growth in the years ahead.”

“Our team delivered another quarter of exceptional growth for Shield, and we are excited about several important milestones that reinforce its expanding role in colorectal cancer screening,” said AmirAli Talasaz, co-founder and co-CEO. “The inclusion of the Shield blood test in the American Cancer Society’s screening guidelines, together with UnitedHealth Group’s broad coverage decision, represents powerful validation of Shield’s clinical utility and its potential to improve access to screening.”

Second Quarter 2026 Financial Results

Revenue was $335.0 million for the second quarter of 2026, a 44% increase from $232.1 million for the corresponding prior year period. Oncology revenue grew 38% to $219.1 million for the second quarter of 2026, from $158.7 million for the corresponding prior year period, driven primarily by an increase in Oncology test volume, which grew 63% over the prior year period. Screening revenue grew over 250% to $52.9 million for the second quarter of 2026, from $14.8 million for the corresponding prior year period, driven primarily by an increase in Shield screening test volume, which grew to approximately 66,000 tests in the second quarter of 2026, from approximately 16,000 tests in the prior year period. Biopharma & Data revenue grew 9% to $60.9 million for the second quarter of 2026, from $56.0 million for the corresponding prior year period. Licensing and other revenue was $2.1 million for the second quarter of 2026, compared to $2.6 million for the corresponding prior year period.

Gross profit, or total revenue less cost of revenue, was $219.0 million for the second quarter of 2026, an increase of $68.1 million or 45%, from $150.9 million for the corresponding prior year period. Gross margin, or gross profit divided by total revenue, was 65% for the second quarter of 2026, as compared to 65% for the corresponding prior year period.

Non-GAAP gross profit was $223.1 million for the second quarter of 2026, an increase of $69.3 million or 45%, from $153.8 million for the corresponding prior year period. Non-GAAP gross margin was 67% for the second quarter of 2026, as compared to 66% for the corresponding prior year period.

Operating expenses were $348.1 million for the second quarter of 2026, as compared to $257.3 million for the corresponding prior year period. The year-over-year increase in operating expenses was primarily related to commercial infrastructure expansion and marketing activities to support the Shield and Oncology growth and an increase in stock-based compensation. Non-GAAP operating expenses were $288.3 million for the second quarter of 2026, as compared to $215.3 million for the corresponding prior year period. The year-over-year increase in non-GAAP operating expenses was primarily related to commercial infrastructure expansion and marketing activities to support the Shield and Oncology growth.

Net loss was $120.1 million for the second quarter of 2026, as compared to $99.9 million for the corresponding prior year period. Net loss per share was $0.90 for the second quarter of 2026, as compared to $0.80 for the corresponding prior year period.

Non-GAAP net loss was $56.2 million for the second quarter of 2026, as compared to $55.0 million for the corresponding prior year period. Non-GAAP net loss per share was $0.42 for the second quarter of 2026, as compared to $0.44 for the corresponding prior year period.

Adjusted EBITDA loss was $55.9 million for the second quarter of 2026, as compared to a $51.9 million loss for the corresponding prior year period.

Free cash flow for the second quarter of 2026 was $(69.5) million, as compared to $(65.9) million for the corresponding prior year period.

Cash, cash equivalents, and restricted cash were $1.2 billion as of June 30, 2026.

2026 Guidance

Guardant Health now expects full year 2026 revenue to be in the range of $1.34 to $1.36 billion, representing growth of 36% to 38% compared to full year 2025. This compares to the prior range of $1.30 to $1.32 billion, representing growth of 32% to 34%.

Within this revenue range:

•Oncology revenue is now expected to grow approximately 30% in 2026, compared to prior guidance of 28% to 29%. Oncology volume is now expected to grow to approximately 50% in 2026, compared to prior guidance of approximately 35%.

•Biopharma & Data revenue growth is expected to be in the low double-digit range.

•Screening revenue is now expected to be in the range of $218 to $230 million, driven by Shield volume of 270,000 to 285,000 tests. This compares to the prior guidance of $186 to $198 million revenue and 230,000 to 245,000 tests.

Guardant Health continues to expect full year 2026 non-GAAP gross margin to be in the range of 64% to 65%. Guardant Health now expects total non-GAAP operating expenses to be in the range of $1.08 to $1.10 billion, an increase compared to the prior range of $1.05 to $1.07 billion. Guardant Health now expects full-year free cash flow burn of $195 million to $205 million, compared with its previous outlook of $185 million to $195 million. The revised range reflects accelerated investment in laboratory capacity to support rapid Shield volume growth and represents an improvement from the $233 million of free cash flow burn reported for full-year 2025.

Webcast Information

Guardant Health will host a conference call to discuss the second quarter 2026 financial results after market close on Thursday, July 30, 2026 at 1:30 pm Pacific Time / 4:30 pm Eastern Time. A webcast of the conference call can be accessed at http://investors.guardanthealth.com. The webcast will be archived and available for replay for at least 90 days after the event.

Non-GAAP Measures

Guardant Health has presented in this release certain financial information in accordance with U.S. Generally Accepted Accounting Principles (GAAP) and also on a non-GAAP basis, including non-GAAP cost of revenue, non-GAAP gross profit, non-GAAP research and development expense, non-GAAP sales and marketing expense, non-GAAP general and administrative expense, non-GAAP loss from operations, non-GAAP net loss, non-GAAP net loss per share, basic and diluted, adjusted EBITDA, and free cash flow.

We define our non-GAAP measures as the applicable GAAP measure adjusted for the impacts of stock-based compensation and related employer payroll tax payments, contingent consideration, amortization of intangible assets, impairment of non-marketable equity securities, gain on extinguishment of convertible notes, and other non-recurring items.

Adjusted EBITDA is defined as net loss adjusted for interest income; interest expense; other income (expense), net; provision for income taxes; depreciation and amortization expense; stock-based compensation expense and related employer payroll tax payments; contingent consideration; and other non-recurring items. Free cash flow is defined as net cash used in operating activities in the period less purchases of property and equipment in the period.

We believe that the exclusion of certain income and expenses in calculating these non-GAAP financial measures can provide a useful measure for investors when comparing our period-to-period core operating results, and when comparing those same results to that published by our peers. We exclude certain items because we believe that these income and expenses do not reflect expected future operating performance. Additionally, certain items are inconsistent in amounts and frequency, making it difficult to perform a meaningful evaluation of our current or past operating performance. We use these non-GAAP financial measures to evaluate ongoing operations, for internal planning and forecasting purposes, and to manage our business.

These non-GAAP financial measures are not intended to be considered in isolation from, as substitute for, or as superior to, the corresponding financial measures prepared in accordance with GAAP. There are limitations inherent in non-GAAP financial measures because they exclude charges and credits that are required to be included in a GAAP presentation, and do not present the full measure of our recorded costs against its revenue. In addition, our definition of the non-GAAP financial measures may differ from non-GAAP measures used by other companies.

About Guardant Health

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2025, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.

Investor Contact:

Zarak Khurshid

investors@guardanthealth.com

Media Contact:

Meaghan Smith

press@guardanthealth.com

Guardant Health, Inc.

Condensed Consolidated Statements of Operations

(unaudited)

(in thousands, except per share data)

Three Months Ended June 30, Six Months Ended June 30,

2026 2025 2026 2025

Revenue $ 334,978 $ 232,088 $ 636,643 $ 435,559

Costs and operating expenses:

Cost of revenue 115,949 81,205 220,868 155,928

Research and development expense 96,533 87,449 187,571 175,970

Sales and marketing expense 189,954 119,588 359,086 223,904

General and administrative expense 61,660 50,259 119,586 97,211

Total costs and operating expenses 464,096 338,501 887,111 653,013

Loss from operations (129,118) (106,413) (250,468) (217,454)

Interest income 10,199 7,560 21,350 16,672

Interest expense (1,346) (983) (2,693) (1,774)

Other income (expense), net 308 (25) 151 7,826

Loss before provision for income taxes

(119,957) (99,861) (231,660) (194,730)

Provision for income taxes

185 38 557 328

Net loss $ (120,142) $ (99,899) $ (232,217) $ (195,058)

Net loss per share, basic and diluted $ (0.90) $ (0.80) $ (1.76) $ (1.57)

Weighted-average shares used in computing net loss per share, basic and diluted 132,867 124,114 132,074 123,993

Guardant Health, Inc.

Condensed Consolidated Balance Sheets

(unaudited)

(in thousands, except share and per share data)

June 30, 2026 December 31, 2025

ASSETS

Current assets:

Cash and cash equivalents

$ 1,053,469 $ 378,203

Short-term marketable securities

— 823,395

Accounts receivable, net

144,249 137,849

Inventory, net

105,463 85,876

Prepaid expenses and other current assets, net

61,458 40,723

Total current assets

1,364,639 1,466,046

Restricted cash 114,270 111,214

Property and equipment, net

155,299 145,915

Right-of-use assets, net

147,566 158,849

Intangible assets, net

25,267 25,921

Goodwill

77,257 77,257

Other assets, net

27,996 28,457

Total Assets

$ 1,912,294 $ 2,013,659

LIABILITIES AND STOCKHOLDERS’ DEFICIT

Current liabilities:

Accounts payable $ 93,514 $ 54,442

Accrued compensation 121,366 119,646

Accrued expenses

79,291 77,889

Deferred revenue

44,791 50,753

Total current liabilities

338,962 302,730

Convertible senior notes, net

1,502,943 1,504,000

Long-term operating lease liabilities

166,312 178,463

Other long-term liabilities

126,944 127,773

Total Liabilities

2,135,161 2,112,966

Stockholders’ deficit:

Common stock, par value of $0.00001 per share; 350,000,000 shares authorized; 133,612,678 and 130,635,301 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively

1 1

Additional paid-in capital

3,009,424 2,900,056

Accumulated other comprehensive loss

(5,563) (4,852)

Accumulated deficit

(3,226,729) (2,994,512)

Total Stockholders’ Deficit

(222,867) (99,307)

Total Liabilities and Stockholders’ Deficit

$ 1,912,294 $ 2,013,659

Guardant Health, Inc.

Supplemental Revenue Information

(unaudited)

(in thousands)

Three Months Ended June 30, Six Months Ended June 30,

2026 2025 2026 2025

Oncology $ 219,105 $ 158,685 $ 424,059 $ 309,244

Biopharma and data

60,947 56,020 113,924 101,396

Screening 52,866 14,814 94,456 20,491

Licensing and other

2,060 2,569 4,204 4,428

Total revenue $ 334,978 $ 232,088 $ 636,643 $ 435,559

Reconciliation of Selected GAAP Measures to Non-GAAP Measures

(unaudited)

(in thousands, except per share data)

Three Months Ended June 30, Six Months Ended June 30,

2026 2025 2026 2025

GAAP cost of revenue

$ 115,949 $ 81,205 $ 220,868 $ 155,928

Amortization of intangible assets (150) (150) (298) (298)

Stock-based compensation expense and related employer payroll tax payments (3,945) (2,759) (7,156) (5,149)

Non-GAAP cost of revenue

$ 111,854 $ 78,296 $ 213,414 $ 150,481

GAAP gross profit $ 219,029 $ 150,883 $ 415,775 $ 279,631

Amortization of intangible assets 150 150 298 298

Stock-based compensation expense and related employer payroll tax payments 3,945 2,759 7,156 5,149

Non-GAAP gross profit $ 223,124 $ 153,792 $ 423,229 $ 285,078

GAAP research and development expense $ 96,533 $ 87,449 $ 187,571 $ 175,970

Stock-based compensation expense and related employer payroll tax payments (16,025) (14,255) (30,474) (27,345)

Contingent consideration — (647) — (1,181)

Non-GAAP research and development expense $ 80,508 $ 72,547 $ 157,097 $ 147,444

GAAP sales and marketing expense $ 189,954 $ 119,588 $ 359,086 $ 223,904

Stock-based compensation expense and related employer payroll tax payments (17,594) (11,756) (32,296) (21,945)

Non-GAAP sales and marketing expense $ 172,360 $ 107,832 $ 326,790 $ 201,959

GAAP general and administrative expense $ 61,660 $ 50,259 $ 119,586 $ 97,211

Amortization of intangible assets (126) (266) (356) (598)

Stock-based compensation expense and related employer payroll tax payments (24,842) (14,832) (44,351) (28,403)

Contingent consideration (1,000) (230) (1,000) (720)

Other

(250) — (1,400) (2,000)

Non-GAAP general and administrative expense $ 35,442 $ 34,931 $ 72,479 $ 65,490

Three Months Ended June 30, Six Months Ended June 30,

2026 2025 2026 2025

GAAP loss from operations $ (129,118) $ (106,413) $ (250,468) $ (217,454)

Amortization of intangible assets 276 416 654 896

Stock-based compensation expense and related employer payroll tax payments 62,406 43,602 114,277 82,842

Contingent consideration 1,000 877 1,000 1,901

Other

250 — 1,400 2,000

Non-GAAP loss from operations $ (65,186) $ (61,518) $ (133,137) $ (129,815)

GAAP net loss $ (120,142) $ (99,899) $ (232,217) $ (195,058)

Amortization of intangible assets 276 416 654 896

Stock-based compensation expense and related employer payroll tax payments 62,406 43,602 114,277 82,842

Contingent consideration 1,000 877 1,000 1,901

Impairment of non-marketable equity securities

— — — 5,000

Gain on extinguishment of convertible notes — — — (13,672)

Other

250 — 1,400 2,000

Non-GAAP net loss $ (56,210) $ (55,004) $ (114,886) $ (116,091)

GAAP net loss per share, basic and diluted $ (0.90) $ (0.80) $ (1.76) $ (1.57)

Non-GAAP net loss per share, basic and diluted $ (0.42) $ (0.44) $ (0.87) $ (0.94)

Weighted-average shares used in computing GAAP and Non-GAAP net loss per share, basic and diluted 132,867 124,114 132,074 123,993

Reconciliation of GAAP Net Loss to Adjusted EBITDA

(unaudited)

(in thousands)

Three Months Ended June 30, Six Months Ended June 30,

2026 2025 2026 2025

GAAP net loss $ (120,142) $ (99,899) $ (232,217) $ (195,058)

Interest income (10,199) (7,560) (21,350) (16,672)

Interest expense 1,346 983 2,693 1,774

Other expense (income), net (308) 25 (151) (7,826)

Provision for income taxes

185 38 557 328

Depreciation and amortization 9,561 10,042 19,003 20,278

Stock-based compensation expense and related employer payroll tax payments 62,406 43,602 114,277 82,842

Contingent consideration 1,000 877 1,000 1,901

Other

250 — 1,400 2,000

Adjusted EBITDA $ (55,901) $ (51,892) $ (114,788) $ (110,433)

Reconciliation of Free Cash Flow to Net Cash Used in Operating Activities

(unaudited)

(in thousands)

Three Months Ended June 30, Six Months Ended June 30,

2026 2025 2026 2025

Net cash used in operating activities $ (57,778) $ (60,285) $ (123,401) $ (122,974)

Purchases of property and equipment (11,759) (5,649) (17,339) (10,108)

Free cash flow $ (69,537) $ (65,934) $ (140,740) $ (133,082)

GRAPHIC

Filename: image.jpg · Sequence: 6

Binary file (16201 bytes)

Download image.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Document and Entity Information Document

Jul. 30, 2026

Cover [Abstract]

Document Type

8-K

Document Period End Date

Jul. 30, 2026

Entity Registrant Name

GUARDANT HEALTH, INC.

Entity Central Index Key

0001576280

Amendment Flag

false

Entity Incorporation, State or Country Code

Entity File Number

001-38683

Entity Tax Identification Number

45-4139254

Entity Address, Address Line One

3100 Hanover Street

Entity Address, City or Town

Palo Alto

Entity Address, State or Province

Entity Address, Postal Zip Code

94304

City Area Code

855

Local Phone Number

698-8887

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

false

Title of 12(b) Security

Common Stock, $0.00001 par value per share

Trading Symbol

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration